Sambrook P N, Cohen M L, Eisman J A, Pocock N A, Champion G D, Yeates M G
Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, NSW, Australia.
Ann Rheum Dis. 1989 Jul;48(7):535-8. doi: 10.1136/ard.48.7.535.
Low dose corticosteroids are effective in suppressing synovitis in rheumatoid arthritis (RA), but there remains concern about their side effects, particularly osteoporosis. To examine the effects of low dose corticosteroids on bone loss in RA bone mineral density (BMD) was measured in the lumbar spine and hip for up to two years in 15 patients treated with these agents (mean dose prednis(ol)one 6.6 mg/day). 15 patients not receiving them, and 15 age matched controls. The initial BMD at both skeletal sites was significantly reduced in both patient groups compared with controls. The mean change in bone density was 0.2, 0.1, and -0.1% a year in the spine and -2.0, -1.9, and -1.0% a year in the hip respectively for the three groups. These rates of bone loss were not significantly different between groups at either site. These findings suggest that low dose corticosteroid treatment in RA is not associated with an increased risk of osteoporosis.
低剂量皮质类固醇对抑制类风湿关节炎(RA)的滑膜炎有效,但人们仍担心其副作用,尤其是骨质疏松。为了研究低剂量皮质类固醇对RA骨质流失的影响,对15例接受这些药物治疗(泼尼松(龙)平均剂量6.6毫克/天)的患者进行了长达两年的腰椎和髋部骨矿物质密度(BMD)测量。15例未接受治疗的患者以及15例年龄匹配的对照者。与对照组相比,两个患者组两个骨骼部位的初始BMD均显著降低。三组患者脊柱骨密度的年平均变化分别为0.2%、0.1%和 -0.1%,髋部骨密度的年平均变化分别为 -2.0%、-1.9%和 -1.0%。两组在任一部位的骨质流失率均无显著差异。这些发现表明,RA患者接受低剂量皮质类固醇治疗与骨质疏松风险增加无关。